In CRC cells, hypomethylation of the CEACAM5 promoter enhanced CEA expression in HCT116 and HT29 cells with 5‐aza‐2′‐deoxycytidine (5‐Aza‐dC) treatment. The gene discussed is CEACAM5; the disease is colorectal carcinoma.